EP
PRAX icon

Essential Partners’s Praxis Precision Medicines PRAX Stock Holding History

Essential Partners’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.03K Buy
21
+17
+425% +$5.38K ﹤0.01% 1376
2026
Q1 		$1.29K Hold
4
– – ﹤0.01% 2160
2025
Q4 		$1.18K Buy
4
+3
+300% +$559 ﹤0.01% 1978
2025
Q3 		$53 Hold
1
– – ﹤0.01% 2562
2025
Q2 		$42 Buy
+1
New +$38 ﹤0.01% 2163

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Essential Partners's PRAX Position: Q2 2026 in Review

Essential Partners increased its Praxis Precision Medicines (PRAX) stake by 425% in Q2 2026, buying an estimated $5.38K and bringing the position to 21 shares worth $7.03K. The position accounts for ﹤0.01% of the portfolio, ranked #1376.

Essential Partners first reported a position in PRAX in Q2 2025 and has held it in 5 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Essential Partners held 21 shares of Praxis Precision Medicines worth $7.03K as of Q2 2026.
  • Essential Partners bought 17 Praxis Precision Medicines shares in Q2 2026, an estimated $5.38K.
  • Praxis Precision Medicines made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1376 holding.
  • Essential Partners first reported a position in Praxis Precision Medicines in Q2 2025 and has held it in 5 quarters since.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.